Edition:
United States

argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

85.56USD
4:00pm EDT
Change (% chg)

$0.62 (+0.73%)
Prev Close
$84.94
Open
$85.38
Day's High
$85.76
Day's Low
$84.86
Volume
13,103
Avg. Vol
24,972
52-wk High
$103.00
52-wk Low
$20.35

Chart for

About

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused... (more)

Overall

No Ratios Available.

Financials

  ARGX.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -- -- --
ROI: -- 2.89 12.63
ROE: -- 1.65 14.82

BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod

* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS

Jul 25 2018

BRIEF-Argenx Q1 Operating Income Down At 6.9 Million Euros

* ARGENX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 09 2018

BRIEF-Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)

* REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING

Apr 24 2018

BRIEF-Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma

* TO RECEIVE THIRD PRECLINICAL MILESTONE PAYMENT FROM COLLABORATION WITH LEO PHARMA - MILESTONE ASSOCIATED WITH CTA APPROVAL FOR ARGX

Apr 12 2018

BRIEF-Argenx Appoints Keith Woods As Chief Operating Officer

* ARGENX APPOINTS KEITH WOODS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 09 2018

BRIEF-Argenx Appoints Keith Woods As Chief Operating Officer

* ARGENX APPOINTS KEITH WOODS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 09 2018

BRIEF-Argenx ‍To Present Complete Data From Phase 2 Clinical Trial Of Efgartigimod

* ‍TO PRESENT COMPLETE DATA FROM PHASE 2 CLINICAL TRIAL OF EFGARTIGIMOD (ARGX-113) IN MYASTHENIA GRAVIS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 03 2018

BRIEF-Argenx ‍Announces Orphan Drug Designation For Argx-113 For Treatment Of Myasthenia Gravis In Europe​

* ‍ANNOUNCES ORPHAN DRUG DESIGNATION FOR ARGX-113 FOR TREATMENT OF MYASTHENIA GRAVIS IN EUROPE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 26 2018

BRIEF-Argenx Reports Fourth Quarter Business Update And Full Year 2017 Financial Results

* ARGENX REPORTS FOURTH QUARTER BUSINESS UPDATE AND FULL YEAR 2017 FINANCIAL RESULTS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 01 2018

BRIEF-Argenx FY Total Operating Income Rises To 41.3 Million Euros

* FY REVENUE EUR 36.4‍​ MILLION VERSUS EUR 14.7 MILLION YEAR AGO

Mar 01 2018

Earnings vs. Estimates